Back to search results

Study of Out of Specification for Tisagenlecleucel

Abroad (travel likely)RecruitingPHASE3

Conditions

B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Novartis Investigative Site, Hamilton, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Tōon, Ehime, Japan

  • Novartis Investigative Site, Gifu, Gifu, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Kobe, Hyōgo, Japan

  • Novartis Investigative Site, Nishinomiya, Hyōgo, Japan

  • Novartis Investigative Site, Tsukuba, Ibaraki, Japan

  • Novartis Investigative Site, Kita-gun, Kagawa-ken, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Kumamoto, Kumamoto, Japan

  • Novartis Investigative Site, Kyoto, Kyoto, Japan

  • Novartis Investigative Site, Tsu, Mie-ken, Japan

  • Novartis Investigative Site, Sendai, Miyagi, Japan

  • Novartis Investigative Site, Matsumoto, Nagano, Japan

  • Novartis Investigative Site, Nagasaki, Nagasaki, Japan

  • Novartis Investigative Site, Yufu, Oita Prefecture, Japan

  • Novartis Investigative Site, Kurashiki, Okayama-ken, Japan

  • Novartis Investigative Site, Izumi, Osaka, Japan

  • Novartis Investigative Site, Izumisano, Osaka, Japan

  • Novartis Investigative Site, Osaka, Osaka, Japan

  • Novartis Investigative Site, Sakai, Osaka, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Izumo, Shimane, Japan

  • Novartis Investigative Site, Hamamatsu, Shizuoka, Japan

  • Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Fuchū, Tokyo, Japan

  • Novartis Investigative Site, Minato-ku, Tokyo, Japan

  • Novartis Investigative Site, Setagaya-ku, Tokyo, Japan

  • Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site, Aomori, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Ishikawa, Japan

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Niigata, Japan

  • Novartis Investigative Site, Okayama, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Saitama, Japan

  • Novartis Investigative Site, Wakayama, Japan

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)